Terran Biosciences and University of Maryland, Baltimore announce exclusive licensing deal for a portfolio of patents and data
PR94812
Terran Biosciences and University of Maryland, Baltimore announce exclusive licensing deal for a portfolio of patents and data supporting novel innovation in the psychedelic therapeutic space
NEW YORK, March 9, 2022 /PRNewswire=KYODO JBN/ --
Terran Biosciences, Inc. ("Terran") has entered into an agreement with the
University of Maryland, Baltimore ("UMB") for a worldwide exclusive license to
develop and commercialize a portfolio of UMB's patents and data to support a
novel approach to the treatment of neurological and psychiatric illnesses with
psychedelic therapeutics.
Logo - https://mma.prnewswire.com/media/1758607/terran_biosciences_Logo.jpg
With this transaction, Terran further expands their broad pipeline of promising
clinical stage CNS therapeutics and technologies. This intellectual property
and data will also complement Terran's current portfolio of over 150 patents
covering new compounds and applications in the psychedelic therapeutic space.
"We couldn't be more excited about these discoveries at UMB, which are some of
the most innovative we've seen in psychedelic medicine," Dr. Sam Clark,
Terran's CEO, commented, "These data represent a major breakthrough in the
understanding of how psychedelics act on the brain. We look forward to
advancing these assets to help patients suffering from devastating
neuropsychiatric illnesses."
About Terran Biosciences, Inc.
Terran is a biotech platform company developing a portfolio of therapeutics and
technologies for patients with neurological and psychiatric diseases. Backed by
a number of life-science and tech investors, Terran has built a CNS-focused,
tech-enabled drug development platform, and is rapidly advancing of number of
late-stage assets, which include novel psychedelic-based therapeutics.
Terran Contact:
Dustin Tetzl, MD
Chief Business Officer
Terran Biosciences, Inc.
info@terranbiosciences.com
SOURCE Terran Biosciences, Inc.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。